NCT07117877

Etoposide Capsules Combined With Bevacizumab and Iparomlimab and Tuvonralimab in the Treatment of Platinum Resistant or Platinum Refractory Ovarian Cancer

Etoposide Capsules Combined With Bevacizumab and Iparomlimab and Tuvonralimab in the Treatment of Platinum Resistant or Platinum Refractory Ovarian Cancer: a Single Arm, Open, Single Center, Phase II Clinical Study

• Status: Not Yet Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 33 (estimated)
• Sponsor: Fudan University · Academic / Other
• Sex: Female
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This study is a Prospective, Single-arm, Phase II clinical trial. The purpose of this study is to find out if taking Etoposide Capsules combined With Bevacizumab and Iparomlimab and Tuvonralimab is safe and works well for people with platinum-resistant or platinum refractory ovarian cancer . Researchers will look at the Progression-Free Survival, Objective Response Rate, Overall Survival, safety, and any side effects.

Conditions

• Platinum Resistant Ovarian Cancer
• Platinum Refractory Epithelial Ovarian Cancer
• Ovarian Cancer (OvCa)

Interventions

Type	Name	Description
DRUG	Etoposide Capsules	50 mg(25mg/pill, 2 pills at a time) orally, qd, days 1 to 14, per cycle
DRUG	Bevacizumab	7.5mg/kg, i.v, q3w
DRUG	Iparomlimab and Tuvonralimab (QL1706)	5mg/kg, i.v., q3w

Timeline

• Start date: 2025-09-15
• Primary completion: 2026-08-31
• Completion: 2027-08-31
• First posted: 2025-08-12
• Last updated: 2025-08-28

Locations

1 site across 1 country: China